Mitochondrial dysfunction in uremic cardiomyopathy

American Journal of Physiology - Renal Physiology

Volumn 308, Issue 6, 2015, Pages F579-F587

  Taylor, David ^a   Bhandari, Sunil ^b   Seymour, Anne Marie L ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Chronic kidney disease; Mitochondrial dysfunction; Mitochondrial permeability transition pore; Uremic cardiomyopathy

Indexed keywords

CALCIUM; CREATININE; FLAVINE ADENINE NUCLEOTIDE; HYDROGEN PEROXIDE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; OXIDIZING AGENT; CARRIER PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOFLUORESCENCE; CARDIOMYOPATHY; CELL DEATH; CONTROLLED STUDY; CREATININE CLEARANCE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HEART MITOCHONDRION; HEART MUSCLE CELL; MALE; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; UREMIA; UREMIC CARDIOMYOPATHY; ANIMAL; CARDIOMYOPATHIES; CELL CULTURE; CELL RESPIRATION; COMPLICATION; DISEASE MODEL; IN VITRO STUDY; METABOLISM; MITOCHONDRION; MYOCARDIAL REPERFUSION INJURY; SPRAGUE DAWLEY RAT;

ANIMALS; CALCIUM; CARDIOMYOPATHIES; CELL RESPIRATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; IN VITRO TECHNIQUES; MALE; MITOCHONDRIA; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; OXIDATIVE STRESS; RATS, SPRAGUE-DAWLEY; UREMIA;

EID: 84930891204     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00442.2014     Document Type: Article

References (68)

1. Abel ED, Doenst T. Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy. Cardiovasc Res 90: 234-242, 2011.
2. Altschuld R, Gibb L, Ansel A, Hohl C, Kruger FA, Brierley GP. Calcium tolerance of isolated rat heart cells. J Mol Cell Cardiol 12: 1383-1395, 1980.
3. Boehm EA, Jones BE, Radda GK, Veech RL, Clarke K. Increased uncoupling proteins and decreased efficiency in palmitate-perfused hyper-thyroid rat heart. Am J Physiol Heart Circ Physiol 280: H977-H983, 2001.
4. Bosetti F, Baracca A, Lenaz G, Solaini G. Increased state 4 mitochon-drial respiration and swelling in early post-ischemic reperfusion of rat heart. FEBS Lett 563: 161-164, 2004.
5. Boudina S, Sena S, O’Neill BT, Tathireddy P, Young ME, Abel ED. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 112: 2686-2695, 2005.
6. Brandes R, Bers DM. Simultaneous measurements of mitochondrial NADH and Ca(2) during increased work in intact rat heart trabeculae. Biophys J 83: 587-604, 2002.
7. Bugger H, Schwarzer M, Chen D, Schrepper A, Amorim PA, Schoepe M, Nguyen TD, Mohr FW, Khalimonchuk O, Weimer BC, Doenst T. Proteomic remodelling of mitochondrial oxidative pathways in pressure overload-induced heart failure. Cardiovasc Res 85: 376-384, 2010.
8. Byrne CJ, McCafferty K, Kieswich J, Harwood S, Andrikopoulos P, Raftery M, Thiemermann C, Yaqoob MM. Ischemic conditioning protects the uremic heart in a rodent model of myocardial infarction. Circulation 125: 1256-1265, 2012.
9. Chinnappa S, Hothi SS, Tan LB. Is uremic cardiomyopathy a direct consequence of chronic kidney disease? Expert Rev Cardiovasc Ther 12: 127-130, 2014.
10. DeBosch B, Sambandam N, Weinheimer C, Courtois M, Muslin AJ. Akt2 regulates cardiac metabolism and cardiomyocyte survival. J Biol Chem 281: 32841-32851, 2006.
11. Dikow R, Hardt SE. The uremic myocardium and ischemic tolerance: a world of difference. Circulation 125: 1215-1216, 2012.
12. Dikow R, Kihm LP, Zeier M, Kapitza J, Tornig J, Amann K, Tiefenbacher C, Ritz E. Increased infarct size in uremic rats: reduced ischemia tolerance? J Am Soc Nephrol 15: 1530-1536, 2004.
13. Dikow R, Schmidt U, Kihm LP, Schaier M, Schwenger V, Gross ML, Katus HA, Zeier M, Hardt SE. Uremia aggravates left ventricular remodeling after myocardial infarction. Am J Nephrol 32: 13-22, 2010.
14. Dikow R, Wasserhess C, Zimmerer K, Kihm LP, Schaier M, Sch-wenger V, Hardt S, Tiefenbacher C, Katus H, Zeier M, Gross LM. Effect of insulin and glucose infusion on myocardial infarction size in uraemic rats. Basic Res Cardiol 104: 571-579, 2009.
15. Doenst T, Pytel G, Schrepper A, Amorim P, Farber G, Shingu Y, Mohr FW, Schwarzer M. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovasc Res 86: 461-470, 2010.
16. Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis 42: 677-684, 2003.
17. Emaus RK, Grunwald R, Lemasters JJ. Rhodamine 123 as a probe of transmembrane potential in isolated rat-liver mitochondria: spectral and metabolic properties. Biochim Biophys Acta 850: 436-448, 1986.
18. Fink BD, Hong YS, Mathahs MM, Scholz TD, Dillon JS, Sivitz WI. UCP2-dependent proton leak in isolated mammalian mitochondria. J Biol Chem 277: 3918-3925, 2002.
19. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47: 186-192, 1995.
20. Ganote CE, Humphrey SM. Effects of anoxic or oxygenated reperfusion in globally ischemic, isovolumic, perfused rat hearts. Am J Pathol 120: 129-145, 1985.
21. Gao F, Gao E, Yue TL, Ohlstein EH, Lopez BL, Christopher TA, Ma XL. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 105: 1497-1502, 2002.
22. Gong G, Liu J, Liang P, Guo T, Hu Q, Ochiai K, Hou M, Ye Y, Wu X, Mansoor A, From AH, Ugurbil K, Bache RJ, Zhang J. Oxidative capacity in failing hearts. Am J Physiol Heart Circ Physiol 285: H541-H548, 2003.
23. Halestrap AP. What is the mitochondrial permeability transition pore? J Mol Cell Cardiol 46: 821-831, 2009.
24. Halestrap AP, Pasdois P. The role of the mitochondrial permeability transition pore in heart disease. Biochim Biophys Acta 1787: 1402-1415, 2009.
25. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic precon-ditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 288: H971-H976, 2005.
26. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61: 448-460, 2004.
27. Heather LC, Cole MA, Atherton HJ, Coumans WA, Evans RD, Tyler DJ, Glatz JF, Luiken JJ, Clarke K. Adenosine monophosphate-activated protein kinase activation, substrate transporter translocation, and metabolism in the contracting hyperthyroid rat heart. Endocrinology 151: 422-431,2010.
28. Hoffman DL, Salter JD, Brookes PS. Response of mitochondrial reactive oxygen species generation to steady-state oxygen tension: implications for hypoxic cell signaling. Am J Physiol Heart Circ Physiol 292: H101-H108, 2007.
29. Javadov S, Karmazyn M, Escobales N. Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases. J Pharmacol Exp Ther 330: 670-678, 2009.
30. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, Sollott SJ. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113: 1535-1549, 2004.
31. Kennedy D, Omran E, Periyasamy SM, Nadoor J, Priyadarshi A, Willey JC, Malhotra D, Xie Z, Shapiro JI. Effect of chronic renal failure on cardiac contractile function, calcium cycling, and gene expression of proteins important for calcium homeostasis in the rat. J Am Soc Nephrol 14: 90-97, 2003.
32. Kocsis GF, Sárközy M, Bencsik P, Pipicz M, Varga ZV, Pálóczi J, Csonka C, Ferdinandy P, Csont T. Preconditioning protects the heart in a prolonged uremic condition. Am J Physiol Heart Circ Physiol 303: H1229-H1236, 2012.
33. Kokoszka JE, Waymire KG, Levy SE, Sligh JE, Cai J, Jones DP, MacGregor GR, Wallace DC. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 427: 461-465, 2004.
34. Koleganova N, Piecha G, Ritz E, Gross ML. Calcitriol ameliorates capillary deficit and fibrosis of the heart in subtotally nephrectomized rats. Nephrol Dial Transplant 24: 778-787, 2009.
35. Korge P, Yang L, Yang JH, Wang Y, Qu Z, Weiss JN. Protective role of transient pore openings in calcium handling by cardiac mitochondria. J Biol Chem 286: 34851-34857, 2011.
36. Lecoeur H, Borgne-Sanchez A, Chaloin O, El-Khoury R, Brabant M, Langonne A, Porceddu M, Briere JJ, Buron N, Rebouillat D, Pechoux C, Deniaud A, Brenner C, Briand JP, Muller S, Rustin P, Jacotot E. HIV-1 Tat protein directly induces mitochondrial membrane permeabilization and inactivates cytochrome c oxidase. Cell Death Dis 3: e282, 2012.
37. Leite AC, Oliveira HC, Utino FL, Garcia R, Alberici LC, Fernandes MP, Castilho RF, Vercesi AE. Mitochondria generated nitric oxide protects against permeability transition via formation of membrane protein S-nitrosothiols. Biochim Biophys Acta 1797: 1210-1216, 2010.
38. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322: 1561-1566, 1990.
39. Marks A, Macleod C, McAteer A, Murchie P, Fluck N, Smith WC, Prescott GJ, Clark LE, Ali T, Black C. Chronic kidney disease, a useful trigger for proactive primary care? Mortality results from a large U.K. cohort. Fam Pract 30: 282-289, 2013.
40. Matlib MA, Rembert JC, Millard RW, Ashraf M, Rouslin W, Asano G, Greenfield JC Jr, Schwartz A. Mitochondrial function in canine experimental cardiac hypertrophy. J Mol Cell Cardiol 15: 221-232, 1983.
41. McMahon AC, Greenwald SE, Dodd SM, Hurst MJ, Raine AE. Prolonged calcium transients and myocardial remodelling in early experimental uraemia. Nephrol Dial Transplant 17: 759-764, 2002.
42. Miura T, Tanno M. Mitochondria and GSK-3beta in cardioprotection against ischemia/reperfusion injury. Cardiovasc Drugs Ther 24: 255-263, 2010.
43. Miura T, Tanno M. The mPTP and its regulatory proteins: final common targets of signalling pathways for protection against necrosis. Cardiovasc Res 94: 181-189, 2012.
44. Mulligan CM, Sparagna GC, Le CH, De Mooy AB, Routh MA, Holmes MG, Hickson-Bick DL, Zarini S, Murphy RC, Xu FY, Hatch GM, McCune SA, Moore RL, Chicco AJ. Dietary linoleate preserves cardiolipin and attenuates mitochondrial dysfunction in the failing rat heart. Cardiovasc Res 94: 460-468, 2012.
45. Nagoshi T, Matsui T, Aoyama T, Leri A, Anversa P, Li L, Ogawa W, del Monte F, Gwathmey JK, Grazette L, Hemmings BA, Kass DA, Champion HC, Rosenzweig A. PI3K rescues the detrimental effects of chronic Akt activation in the heart during schemia/reperfusion injury. J Clin Invest 115: 2128-2138, 2005.
46. Ng KW, Allen ML, Desai A, Macrae D, Pathan N. Cardioprotective effects of insulin: how intensive insulin therapy may benefit cardiac surgery patients. Circulation 125: 721-728, 2012.
47. Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Changes in the mitochondrial permeability transition pore in aging and age-associated diseases. Mech Ageing Dev 134: 1-9, 2013.
48. Petrosillo G, Casanova G, Matera M, Ruggiero FM, Paradies G. Interaction of peroxidized cardiolipin with rat-heart mitochondrial membranes: induction of permeability transition and cytochrome c release. FEBS Lett 580: 6311-6316, 2006.
49. Petrosillo G, Matera M, Moro N, Ruggiero FM, Paradies G. Mitochondrial complex I dysfunction in rat heart with aging: critical role of reactive oxygen species and cardiolipin. Free Radic Biol Med 46: 88-94, 2009.
50. Petrosillo G, Moro N, Paradies V, Ruggiero FM, Paradies G. Increased susceptibility to Ca(2)-induced permeability transition and to cytochrome c release in rat heart mitochondria with aging: effect of melatonin. J Pineal Res 48: 340-346, 2010.
51. Raine AE, Seymour AM, Roberts AF, Radda GK, Ledingham JG. Impairment of cardiac function and energetics in experimental renal failure. J Clin Invest 92: 2934-2940, 1993.
52. Reddy V, Bhandari S, Seymour AML. Myocardial function, energy provision, and carnitine deficiency in experimental uremia. J Am Soc Nephrol 18: 84-92, 2007.
53. Romashko DN, Marban E, O’Rourke B. Subcellular metabolic transients and mitochondrial redox waves in heart cells. Proc Natl Acad Sci USA 95: 1618-1623, 1998.
54. Rosca MG, Hoppel CL. Mitochondria in heart failure. Cardiovasc Res 88: 40-50, 2010.
55. Rosca MG, Vazquez EJ, Kerner J, Parland W, Chandler MP, Stanley W, Sabbah HN, Hoppel CL. Cardiac mitochondria in heart failure: decrease in respirasomes and oxidative phosphorylation. Cardiovasc Res 80: 30-39, 2008.
56. Sack MN. Mitochondrial depolarization and the role of uncoupling proteins in ischemia tolerance. Cardiovasc Res 72: 210-219, 2006.
57. Saini-Chohan HK, Holmes MG, Chicco AJ, Taylor WA, Moore RL, McCune SA, Hickson-Bick DL, Hatch GM, Sparagna GC. Cardiolipin biosynthesis and remodeling enzymes are altered during development of heart failure. J Lipid Res 50: 1600-1608, 2009.
58. Semple D, Smith K, Bhandari S, Seymour AM. Uremic cardiomyopathy and insulin resistance: a critical role for akt? J Am Soc Nephrol 22: 207-215, 2011.
59. Semple DJ, Bhandari S, Seymour AM. Uremic cardiomyopathy is characterized by loss of the cardioprotective effects of insulin. Am J Physiol Renal Physiol 303: F1275-F1286, 2012.
60. Shroff GR, Frederick PD, Herzog CA. Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J 163: 399-406, 2012.
61. Smith K, Semple D, Aksentijevic D, Bhandari S, Seymour AM. Functional and metabolic adaptation in uraemic cardiomyopathy. Front Biosci (Elite Ed) 2: 1492-1501, 2010.
62. Smolenski RT, Schrader J, de Groot H, Deussen A. Oxygen partial pressure and free intracellular adenosine of isolated cardiomyocytes. Am J Physiol Cell Physiol 260: C708-C714, 1991.
63. Song Y, Yu Q, Zhang J, Huang W, Liu Y, Pei H, Liu J, Sun L, Yang L, Li C, Li Y, Zhang F, Qu Y, Tao L. Increased myocardial ischemia-eperfusion injury in renal failure involves cardiac adiponectin signal deficiency. Am J Physiol Endocrinol Metab 306: E1055-E1064, 2014.
64. Sparagna GC, Chicco AJ, Murphy RC, Bristow MR, Johnson CA, Rees ML, Maxey ML, McCune SA, Moore RL. Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure. J Lipid Res 48: 1559-1570, 2007.
65. Stamm C, Friehs I, Choi YH, Zurakowski D, McGowan FX, del Nido PJ. Cytosolic calcium in the ischemic rabbit heart: assessment by pH-and temperature-adjusted rhod-2 spectrofluorometry. Cardiovasc Res 59: 695-704,2003.
66. Strauss HW, Schöder H. Myocardial imaging for mitochondrial membrane potential. JACC Cardiovasc Imaging 5: 293-296, 2012.
67. Tong H, Chen W, Steenbergen C, Murphy E. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res 87: 309-315, 2000.
68. Wang G, Liem DA, Vondriska TM, Honda HM, Korge P, Pantaleon DM, Qiao X, Wang Y, Weiss JN, Ping P. Nitric oxide donors protect murine myocardium against infarction via modulation of mitochondrial permeability transition. Am J Physiol Heart Circ Physiol 288: H1290-H1295, 2005.